Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data ...
New two-year findings from the Phase 2/3 long-term extension demonstrate sustained disease control through two years, ...
Psychiatric evaluation of the assailant – identified only as “LCH” due to restrictions under the Child Act 2001 – entailed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results